These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38075965)

  • 1. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
    Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
    Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
    Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
    Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of COVID-19 vaccines.
    Graña C; Ghosn L; Evrenoglou T; Jarde A; Minozzi S; Bergman H; Buckley BS; Probyn K; Villanueva G; Henschke N; Bonnet H; Assi R; Menon S; Marti M; Devane D; Mallon P; Lelievre JD; Askie LM; Kredo T; Ferrand G; Davidson M; Riveros C; Tovey D; Meerpohl JJ; Grasselli G; Rada G; Hróbjartsson A; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD015477. PubMed ID: 36473651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
    Li M; Yuan J; Lv G; Brown J; Jiang X; Lu ZK
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
    Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
    JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
    Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach.
    Anastassopoulou C; Hatziantoniou S; Vlachopoulos C; Spanakis N; Tsioufis C; Tsakris A; Lazaros G
    Int J Cardiol; 2022 Jul; 358():136-139. PubMed ID: 35436559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    Stowe J; Miller E; Andrews N; Whitaker HJ
    PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.
    Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A
    Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
    Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
    Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal vascular occlusion following SARS-CoV-2 vaccination: A VAERS database analysis.
    Singh RB; Parmar UPS; Gupta R; Vega Garcia AJ; Cho W; Singh KP; Agarwal A
    Ophthalmol Sci; 2023 Jun; 4(1):100354. PubMed ID: 37362418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
    Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.